Dr. Mary-Ellen Taplin on the Mechanism of Action of Enzalutamide (MDV3100) – Video




Dr. Mary-Ellen Taplin on the Mechanism of Action of Enzalutamide (MDV3100)
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, discusses the unique mechanism of action for the androgen receptor antagonist enzalutamide (Xtandi or MDV3100), which was recently approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. For more prostate cancer resources, visit http://www.onclive.comFrom:OncLiveTVViews:0 0ratingsTime:01:34More inEducation

Continued here:
Dr. Mary-Ellen Taplin on the Mechanism of Action of Enzalutamide (MDV3100) - Video

Related Posts

Comments are closed.